Related Experiment Video
Updated: Aug 12, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
Published on: January 1, 2016
Selection of resistant variants of respiratory pathogens by quinolones
A M Sefton1, J P Maskell, J D Williams
1Department of Medical Microbiology, St Bartholomew's and the Royal London School of Medicine and Dentistry, UK.
Abstract:
Quinolones are widely used in the treatment of respiratory tract infections. However, some disquiet has been expressed over using quinolones for community-acquired pneumonia since their activity is generally rather poor against Streptococcus pneumoniae. In addition, it is known that resistant variants emerge at a fairly high frequency during exposure of Enterobacteriaceae to quinolones; if this also occurred during quinolone treatment of community-acquired pneumonia it could lead to an increased risk of clinical failure. We therefore determined the selection rate of quinolone-resistant variants for six strains of S. pneumoniae, Haemophilus influenzae and Moraxella catarrhalis with nalidixic acid (except for S. pneumoniae), ciprofloxacin, ofloxacin and levofloxacin. We were only able to select resistant variants at low frequency from two of the six strains of S. pneumoniae with ciprofloxacin: no resistant variants were selected by either ofloxacin or levofloxacin. Variants of H. influenzae and M. catarrhalis with decreased susceptibility to quinolones were produced both with more strains and with a greater frequency; however, these variants still remained susceptible according to the NCCLS guidelines. Our study suggests that resistant variants of S. pneumoniae are relatively unlikely to occur in individuals treated with fluoroquinolones especially if they are given quinolones with enhanced anti-gram-positive activity compared to ciprofloxacin.
Insights
Fluoroquinolones are effective for community-acquired pneumonia, with low resistance risk in Streptococcus pneumoniae. Enhanced fluoroquinolones show reduced resistance development in key respiratory pathogens.
Area of Science:
- Microbiology and Infectious Diseases
- Pharmacology and Drug Resistance
Background:
- Quinolones are frequently prescribed for respiratory tract infections, including community-acquired pneumonia (CAP).
- Concerns exist regarding quinolone efficacy against Streptococcus pneumoniae and the potential for rapid emergence of resistance in Enterobacteriaceae.
- This raises questions about the safety and effectiveness of quinolone treatment for CAP.
Purpose of the Study:
- To investigate the selection rate of quinolone-resistant variants in key respiratory pathogens.
- To compare resistance development across different quinolones (nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin) in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
- To assess the risk of resistance emergence during quinolone therapy for CAP.
Main Methods:
- Tested six strains each of S. pneumoniae, H. influenzae, and M. catarrhalis.
- Attempted to select for quinolone-resistant variants using nalidixic acid (except for S. pneumoniae), ciprofloxacin, ofloxacin, and levofloxacin.
- Evaluated the frequency of resistant variant selection and assessed susceptibility according to NCCLS guidelines.
Main Results:
- Resistant variants of S. pneumoniae were selected at low frequency with ciprofloxacin only, and not with ofloxacin or levofloxacin.
- Variants of H. influenzae and M. catarrhalis with decreased susceptibility were produced more frequently.
- Despite decreased susceptibility, H. influenzae and M. catarrhalis variants remained susceptible by NCCLS standards.
Conclusions:
- Quinolone-resistant variants of S. pneumoniae are unlikely to emerge during treatment.
- Fluoroquinolones with enhanced Gram-positive activity may further reduce resistance risk.
- H. influenzae and M. catarrhalis showed increased resistance frequency but remained within susceptible ranges.
Related Concept Videos
Antibiotic Selection
Gene Regulation in Microbial Communities: Quorum Sensing
Development of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance

